Real-world data on seropositive rheumatoid arthritis, then and now: ten-year outcomes of 1151 patients diagnosed between 1997 and 2011
Authors' conclusion
Several clinical outcomes were better in patients who were diagnosed more recently.
Study context
- Population
- Patients with early seropositive rheumatoid arthritis (RA) diagnosed in 1997–2011832 attended 10-year visit
- Participants
- 1,151 patients
- Exposure
- Patients diagnosed 2009-2011 vs earlier diagnosis-year groups
- Outcome
- Clinical parameters including disease activity (DAS28) and function
- Follow-up
- 10 years
Methodological detailsreal-world data, comparison of five diagnosis-year groups, 319 did not attend 10-year visit (e.g. 196 died, 49 moved)
- Real-world data
- Comparison of five diagnosis-year groups
- 319 did not attend 10-year visit (e.g. 196 died, 49 moved)
Main finding
As reported in the abstract
1997-1999
2.9
median · IQR 2.2–3.7
2009-2011
2.3
median · IQR 1.4–3.0
P < 0.001
Observational data: associations, not effects.
Further findings
Proportion with ≥2 swollen joints (46 joint count), 1997-1999 vs 2009-2011 · 10-year visit
- Decreased
- from 33% to 13%
Pain, median (IQR), 1997-1999 vs 2009-2011 · 10-year visit
- Decreased
- from 30 (15, 52) to 25 (6, 51) (p=0.03)
Fatigue, median (IQR), 1997-1999 vs 2009-2011 · 10-year visit
- Decreased
- from 31 (12, 52) to 15 (2, 50) (p=0.012)
Physician global assessment, median (IQR), 1997-1999 vs 2009-2011 · 10-year visit
- Decreased
- from 20 (5, 40) to 0 (0, 5) p<0.001
Proportion with HAQ ≤0.5, 1997-1999 vs 2009-2011 · 10-year visit
- Increased
- from 39% to 49% (p=0.002)
MTX use by the 10-year visit, 1997-1999 vs 2009-2011
- Increased
- from 79% to 96% (p<0.001)
bDMARD use by the 10-year visit, 1997-1999 vs 2009-2011
- Increased
- from 11% to 28% (p=0.001)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →